Tekwani’s team focuses on the disease-causing mechanisms and novel therapeutic and vaccine approaches for a diverse array of pathogens, with the objective of identifying novel mechanisms, targets and strategies for the prevention and treatment of protozoal, bacterial and viral infectious diseases throughout the world.
Tekwani has spent more than 30 years researching tropical parasitic diseases such as malaria and leishmaniasis, vector-borne infectious diseases, and major global health threats. His work has identified potential new targets and sources for therapies against these diseases. Some of his most recent work focuses on developing a targeted drug delivery approach for a safer and more effective antimalarial therapeutic relative to currently used strategies against the disease for U.S. troops and global travelers. His research has been funded by the National Institute of Allergy and Infectious Diseases, World Health Organization (WHO), Medicines for Malaria Venture, Bill & Melinda Gates Foundation, the U.S. Department of Defense, and the U.S. Army Medical Research and Material Command.